Telix Pharmaceuticals Limited
TLX
$17.60
$0.301.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 516.66M | 471.86M | 423.64M | 378.98M | 333.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 516.66M | 471.86M | 423.64M | 378.98M | 333.12M |
| Cost of Revenue | 197.43M | 181.44M | 164.16M | 144.15M | 131.23M |
| Gross Profit | 319.24M | 290.42M | 259.49M | 234.83M | 201.89M |
| SG&A Expenses | 136.64M | 122.95M | 108.34M | 94.33M | 82.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 187.50K | -226.70K | -646.90K | -11.63M | 186.30K |
| Total Operating Expenses | 462.67M | 422.60M | 379.42M | 322.14M | 298.85M |
| Operating Income | 54.00M | 49.26M | 44.23M | 56.84M | 34.27M |
| Income Before Tax | 36.95M | 34.99M | 32.87M | 24.18M | 1.71M |
| Income Tax Expenses | 4.04M | 2.32M | 596.10K | 3.50M | -1.36M |
| Earnings from Continuing Operations | 32.91 | 32.67 | 32.28 | 20.69 | 3.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.91M | 32.67M | 32.28M | 20.69M | 3.06M |
| EBIT | 54.00M | 49.26M | 44.23M | 56.84M | 34.27M |
| EBITDA | 57.74M | 53.04M | 48.03M | 60.40M | 37.78M |
| EPS Basic | 0.10 | 0.10 | 0.10 | 0.06 | 0.01 |
| Normalized Basic EPS | 0.09 | 0.08 | 0.07 | 0.09 | 0.05 |
| EPS Diluted | 0.10 | 0.10 | 0.10 | 0.06 | 0.01 |
| Normalized Diluted EPS | 0.09 | 0.08 | 0.07 | 0.09 | 0.05 |
| Average Basic Shares Outstanding | 1.32B | 1.31B | 1.30B | 1.28B | 1.28B |
| Average Diluted Shares Outstanding | 1.38B | 1.36B | 1.34B | 1.31B | 1.29B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
